Multi-target approaches in metabolic syndrome

  • Metabolic syndrome (MetS) is a highly prevalent disease cluster worldwide. It requires polypharmacological treatment of the single conditions including type II diabetes, hypertension, and dyslipidemia, as well as the associated comorbidities. The complex treatment regimens with various drugs lead to drug-drug interactions and inadequate patient adherence, resulting in poor management of the disease. Multi-target approaches aim at reducing the polypharmacology and improving the efficacy. This review summarizes the medicinal chemistry efforts to develop multi-target ligands for MetS. Different combinations of pharmacological targets in context of in vivo efficacy and future perspective for multi-target drugs in MetS are discussed.

Export metadata

Author:Felix F. Lillich, John D. Imig, Ewgenij ProschakORCiDGND
Parent Title (English):Frontiers in Pharmacology
Publisher:Frontiers Media
Place of publication:Lausanne
Document Type:Article
Date of Publication (online):2021/03/12
Date of first Publication:2021/03/12
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2021/08/17
Tag:farnesoid X receptor; metabolic sydrome; multi-target drug; peroxisome prolifer ators-activated receptor-γ; polypharmacology; soluble epoxide hydrolase
Issue:art. 554961
Page Number:18
First Page:1
Last Page:18
EP was supported by the German Research Foundation (DFG, Heisenberg-Professur PR1405/7-1 and SFB 1039 TP A07). JI was supported by a National Institute of Health (NIH) grant (DK103616) and Ralph and Marian Falk Medical Research Trust Bank of America, N.A., Trustee grant.
Institutes:Biochemie, Chemie und Pharmazie
Dewey Decimal Classification:5 Naturwissenschaften und Mathematik / 57 Biowissenschaften; Biologie / 570 Biowissenschaften; Biologie
6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Open-Access-Publikationsfonds:Biochemie, Chemie und Pharmazie
Licence (German):License LogoCreative Commons - Namensnennung 4.0